ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the
